|
Endonovo Therapeutics, Inc. (ENDV) is a biotechnology company developing off the-shelf, cell-free regenerative products and non-invasive, bioelectronic therapies designed to extend and enhance the human life by regenerating tissues and organs that have become injured or damaged due to disease and age.
ENDV is developing therapies for various inflammatory, autoimmune and degenerative diseases utilizing their bio-electromagnetic platform.
Non-invasive treatment for acute and chronic inflammatory conditions of the liver
Earlier this year, ENDV announced its "intention to begin pre-clinical testing of its electroceutical technology to treat and reverse acute and chronic inflammatory liver pathologies." This includes the conditions that cause nonalcoholic steatohepatitis (NASH) and human cirrhotic liver disease, an Apr. 8 press release stated.
"We believe Endonovo's proprietary electroceutical technology holds great promise for the treatment of inflammatory conditions of hepatic origin, furthermore addressing NASH and human cirrhotic liver disease with a non-invasive and safe medical device," said ENDV's chairman and CEO Alan Collier in the Apr. 8 press release.
"Significant, traditionally pharmaceutically-driven companies are now pivoting towards non-invasive electrotherapies. As the overall market gains a greater understanding of the physics of biology, the opportunity to develop effective therapies that act at the biophysical level improves. Endonovo is at the forefront of that opportunity and we foresee the day where virtually untreatable conditions, such as human cirrhotic liver and many other organ diseases, may be treated in such a fashion."
Market opportunity
The American Liver Foundation estimates that up to 30% of the U.S. population is affected by non-alcoholic fatty liver diseases, including NASH and other obesity related liver ailments, the Apr. 8 press release stated.
NASH is liver inflammation and cellular damage caused by a buildup of fat in the liver. NASH occurs in people who drink little or no alcohol, especially people who are middle-aged and overweight or obese.
Approximately 20% of NASH cases result in scarring of the liver and cirrhosis if untreated, with the most acute cases often requiring liver transplantation. There are no approved therapies for the treatment of NASH and there are few pharmaceutical therapies nearing approval over the next several years.
Why ENDV's approach is different
"The fact that all biochemical activity is conducted on an electrochemical infrastructure means that using electromagnetic technologies allows us to 'get behind' the biochemistry, thereby avoiding many of the problems with pharmacological therapies and act at the source of the pathology," said ENDV's chief medical officer Dr. Leonard Makowka in the Apr. 8 press release. "For a century we have taken for granted that electromagnetic technologies, like MRI and CAT, are universally applicable and reliable. At Endonovo, we are simply taking this concept - the fundamental and universal validity and reliability of accessing biology at the electromagnetic level - into the therapeutic realm.
"More specifically, we are focusing on areas with critical unmet clinical needs, which include everything from acute inflammatory hepatic injury to end stage fibrotic liver disease. A non-invasive and safe therapeutic that can effectively address these acute and chronic irreversible and terminal conditions will be a life saver for millions of patients. This is where the promise and potential of the electroceutical technology lies."
To learn more about ENDV, visit: http://endonovo.com
Disclaimer:
This is a paid profile. Do not base any investment decision upon any of the materials found in this publication or on our Web site.
The information contained on our website or in any of our newsletters is for informational purposes only, and is not intended to be advice, nor a recommendation and/or guidance for investment decisions. In preparing our publications, we rely upon publicly available information including press releases which we believe to be reliable, but have not verified. Past performance does not guarantee future results. We are engaged in the business of profiling companies for monetary compensation. All direct and third party compensation received has been disclosed in our newsletter and/or our website in accordance with section 1 7 ( b ) of the Secur ities Act of 1 9 33.
Compensation: We expect to receive five thousand dollars from a third party, Galaxy, LLC, for a one-day e-mail campaign for Endonovo Therapeutics, Inc.
|
